吲唑-1-羧酸甲酯 | 58965-32-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 吲唑-1-羧酸甲酯
• 英文名称: indazole-1-carboxylic acid methyl ester
• 英文别名: methyl 1-indazolecarboxylate；Indazol-1-carbonsaeure-methylester；Methyl indazole-1-carboxylate
• CAS: 58965-32-5
• 化学式: C₉H₈N₂O₂
• 分子量: 176.175
• InChiKey: SOFXDHKUELFSQW-UHFFFAOYSA-N

物化性质

• 熔点：
  59-60 °C
• 沸点：
  304.8±25.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  吲唑-1-羧酸甲酯 在 (THF)Li(TMP)Zn(tBu)2 作用下， 以 四氢呋喃 为溶剂， 生成 methyl (2-cyanophenyl)carbamate
  参考文献：
  名称：

  Alkali-metal mediated zincation of N-heterocyclic substrates using the lithium zincate complex, (THF)Li(TMP)Zn(tBu)2 and applications in in situ cross coupling reactions

  摘要：

  This study investigates the ability of the mixed-metal reagent [Li(TMP)Zn(tBu)(2)] 1 to promote direct Zn-H exchange reactions (zincations) of a wide range of N-heterocyclic molecules. The generated metallated intermediates from these reactions are intercepted with I-2 and some of them are also employed as precursors in Pd-catalysed Negishi cross-coupling applications. A comparison with recent precedents in metallation chemistry reveals that for some of these heterocycles, 1 allows improved conversions, under milder conditions and in certain cases, even gives unique regioselectivities. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.06.090
• 作为产物：
  描述：

  2-aminobenzaldehyde oxime 在 吡啶 、 sodium carbonate 作用下， 生成 吲唑-1-羧酸甲酯
  参考文献：
  名称：

  v. Auwers; Frese, Justus Liebigs Annalen der Chemie, 1926, vol. 450, p. 273

  摘要：

  DOI：

文献信息

• Synthesis and Structural Characterization of 1- and 2-Substituted Indazoles: Ester and Carboxylic Acid Derivatives
  作者：Fátima Teixeira、Hélène Ramos、Inês Antunes、M. Curto、M. Duarte、Isabel Bento

  DOI：10.3390/11110867

  日期：——

  ester-containing side chains -(CH2)(n)CO2R of different lengths (n = 0-6, 9, 10) are described. Nucleophilic substitution reactions on halo esters (X(CH2)(n)CO2R) by 1H-indazole inalkaline solution lead to mixtures of N-1 and N-2 isomers, in which the N-1 isomer predominates. Basic hydrolysis of the ester derivatives allowed the synthesis of the corresponding indazole carboxylic acids. All compounds were

  描述了一系列在 N-1 和 N-2 位置被不同长度 (n = 0-6, 9, 10) 的含酯侧链 -(CH2)(n)CO2R 取代的吲唑。1H-吲唑碱性溶液对卤代酯 (X( )(n)CO2R) 的亲核取代反应导致 N-1 和 N-2 异构体的混合物，其中 N-1 异构体占主导地位。酯衍生物的碱性水解允许合成相应的吲唑羧酸。所有化合物均通过多核 NMR 和 IR 光谱、MS 光谱和元素分析进行​​了充分表征；NMR光谱数据用于N-1和N-2异构体的结构分配。吲唑-2-基-乙酸 (5b) 的分子结构由 X 射线衍射确定，其显示出涉及 O2-H...N1 分子间氢键的超分子结构。
• Synthesis of indazoles from 2-formylphenylboronic acids
  作者：Vitalii V. Solomin、Alberts Seins、Aigars Jirgensons

  DOI：10.1039/d1ra04056a

  日期：——

  synthesis of indazoles was developed which involves a copper(II) acetate catalysed reaction of 2-formylboronic acids with diazadicaboxylates followed by acid or base induced ring closure. Hydrazine dicarboxylates were also shown as competent reaction partners for the synthesis of indazoles, however, they required a stoichiometric amount of copper(II) acetate for the C–N bond formation step. The transformation

  开发了一种合成吲唑的方法，该方法包括乙酸铜 ( II ) 催化的 2-甲酰基硼酸与二氮杂二羧酸盐的反应，然后是酸或碱诱导的闭环。肼二羧酸盐也被证明是合成吲唑的有效反应伙伴，然而，它们需要化学计量数量的乙酸铜 ( II ) 来形成 C-N 键。该转化可以作为两步一锅法有效地进行，得到一系列 1 N-烷氧羰基吲唑。
• [EN] SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT<br/>[FR] AGONISTES DES RÉCEPTEURS DE LA SPHINGOSINE-1-PHOSPHATE, LEURS PROCÉDÉS DE PRÉPARATION, ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT EN TANT QUE PRINCIPE ACTIF
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2014129796A1

  公开（公告）日：2014-08-28

  The present invention relates to novel compounds of Formula 1 as sphingosine-1-phosphate receptor agonists which can be effectively used for the treatment of autoimmune diseases, a method for preparing the same, and a pharmaceutical composition comprising the same as an active component. The compounds according to the present invention are effective on extensive autoimmune diseases and chronic inflammatory diseases including relapsing-remitting multiple sclerosis, and can also be used for treating or preventing immunoregulation disorders.

  本发明涉及一种新的化合物，其化学式为Formula 1，作为鞘氨醇-1-磷酸受体激动剂，可有效用于治疗自身免疫性疾病，以及一种制备该化合物的方法和包含该化合物作为活性成分的药物组合物。根据本发明的化合物对广泛的自身免疫性疾病和慢性炎症性疾病，包括复发-缓解型多发性硬化症等具有有效作用，并且还可用于治疗或预防免疫调节紊乱。
• SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT
  申请人：LG LIFE SCIENCES LTD.

  公开号：US20150376173A1

  公开（公告）日：2015-12-31

  The present invention relates to novel compounds of Formula 1 as sphingosine-1-phosphate receptor agonists which can be effectively used for the treatment of autoimmune diseases, a method for preparing the same, and a pharmaceutical composition comprising the same as an active component. The compounds according to the present invention are effective on extensive autoimmune diseases and chronic inflammatory diseases including relapsing-remitting multiple sclerosis, and can also be used for treating or preventing immunoregulation disorders.

  本发明涉及一种新型化合物，其化学式为1，作为鞘氨醇-1-磷酸受体激动剂，可有效用于治疗自身免疫性疾病，以及制备该化合物的方法和包含该化合物作为活性成分的制药组合物。本发明的化合物对广泛的自身免疫性疾病和慢性炎症性疾病，包括复发缓解型多发性硬化症等具有疗效，并可用于治疗或预防免疫调节失调。
• v. Auwers; Schaich, Chemische Berichte, 1921, vol. 54, p. 1744
  作者：v. Auwers、Schaich

  DOI：——

  日期：——